Hospira chair to leave at year's end; Shire's Vyvanse performs in depression trial;

FiercePharma:  AstraZeneca's cutting 1,150 sales jobs, about 24% of U.S. organization. Release | Follow @FiercePharma

> Hospira ($HSP) Chairman Christopher Begley will bow out at the end of the year, giving recently appointed CEO F. Michael Ball free rein to tackle the company's manufacturing problems. News

> Shire's ($SHPGY) Vyvanse, approved for treating attention deficit hyperactivity disorder, delivered positive results as an add-on drug to improve cognition in patients with major depression. Item

> U.K. cost-effectiveness watchdogs have asked Merck ($MRK) for new data on its respiratory drug Daxas, saying it's likely to be used as an add-on therapy and should be studied in that context. Story

> Sinclair IS Pharma has agreed to buy Advanced Bio-Technologies for £20 million ($31.4 million) in cash and stock, gaining access to ABT's scar prevention and treatment product in more markets. Report

> Cubist Pharmaceuticals ($CBST) extended its offer for Adolor shares at $4.25 per share, saying 75% of the company's shares had been tendered during the first offering period. Article

> Amgen ($AMGN) said more than 98 million of its common shares were tendered in its $60-per-share modified Dutch auction. News

> AstraZeneca ($AZN) purchased 785,806 of its own shares at 2920 pence each as part of its stock buyback plan. Story

> Sun Pharmaceutical Industries founder and Chairman Dilip Shanghvi snapped up 3% of Natco Pharma as a personal investment. Report

> Watson Pharmaceuticals ($WPI) has launched a knockoff version of Teva Pharmaceutical Industries' ($TEVA) birth control pill LoSeasonique. Item

Biotech News

@FierceBiotech: 5 Innovative Michigan device/diagnostic companies. Fascinating tech profiled here by @FierceMedDev. Report | Follow @FierceBiotech

@JohnCFierce: Auxilium (Xiaflex) gets a sales guy to run the company. Punch up sales, work a deal? Maybe. But what biotech isn't in play these days? | Follow @JohnCFierce

@MaureenFierce: Report: Cancer vaccines, flu vaccines, and pneumococcal vaccines will experience the most growth in coming years. | Follow @MaureenFierce

 @FierceMedDev: Abbott starts trial to evaluate the Absorb bioresorbable vascular scaffold versus metallic DES. Release | Follow @FierceMedDev

> Roche, Novartis showcase game-changing breast cancer drug data. Article

> Affymax spikes after expert panel backs new anemia drug rival to Amgen. Story

Vaccines News

> Study: Afternoon vaccines may be better for babies. Report

> EU wants power to negotiate flu vaccine prices. Story

> Takeda unveils new vaccine business headed by Gates Foundation exec. News

> LigoCyte posts positive results from norovirus vaccine trial. Item

Manufacturing News

> Catalent to go disposable in new plant. News

> Analysts ponder takeover of ailing Hospira. Article

> CMO capacity expansions mirror market. Report

> FDA notes lack of Novartis exec response in 3-site warning. News

> Samsung, Biogen Idec team on biosimilars. Story

> Pfizer briefs NJ public on Superfund site cleanup. Item

And Finally... EU officials want joint-purchasing power on vaccines to push prices down and ensure access. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.